CNAT News and Press, Conatus Pharmaceuticals From 01/28/19

SAN DIEGO, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced publications expanding on previously reported results from three of the company’s completed Phase 2 clinical trials. Mitchell Schiffman, M.D., is the lead author on a new pub...

Dear ESSENTIAL subscribers: Hi! I'm Seeking Alpha managing editor Mike Taylor. Welcome to ESSENTIAL Weekly, a subscriber-exclusive look at Seeking Alpha's top news and analysis. I'll guide you through this week's market themes, highlight some analysis you might have missed, and preview comin...

Previously, I analyzed the NASH cirrhosis space from a scientific perspective, comparing and contrasting the antifibrotic drugs Selonsertib ( GILD ), Emricasan ( CNAT ), and GR-MD-02 ( GALT ), whichwas recently assigned the USAN name belapectin . In retrospect, Allergan’s ( AGN ) cenic...

Healthcare investors are enjoying a rousing start to the week after Eli Lilly announced its takeover of Loxo Oncology and the release of a multitude of preliminary 2018 results for presenters at JPMorgan's 2019 Healthcare Conference (JPM19). The SPDR S&P Biotech ETF ( XBI +4.8% ) is up...

Recently, Merck ( MRK ) expanded an old research collaboration with one of its partners known as NGM Biopharmaceuticals, Inc. ( NGM ). The newly expanded deal was made to include an option to license a NASH product from the pipeline. This product showed some pretty good preliminary data ...

If lies are more comforting to you than facts, you need to get out of your comfort zone. ” - DaShanne Stokes Biotech seems to be off to a good start to begin 2019. After early losses on Thursday, the sector reversed and ended the day up one and half percent. The January effect se...

CORAL GABLES, FL / ACCESSWIRE / December 31,2018 / The healthcare sector is complex, this much is certain, but amidst the intricacies of the industry exists companies who are determined to innovate towards creating the best quality of care for patients in the space. Companies in the healt...

CNBC reports that nonalcoholic steatohepatitis or NASH is "next big thing" for drug makers, a potential market of $35B or more if pharma/biotech firms can successfully navigate the regulatory process, a task none has accomplished to date. More news on: Intercept Pharmaceuticals, Madrigal...

Recently, Gilead Sciences ( GILD ) announced that it had entered into a strategic collaboration with a company by the name of Scholar Rock Holding Corporation ( SRRK ). The reason for this deal is so that Gilead could gets its hands on another type of technology to target the ever growin...

"Nothing can dim the light that shines from within" - Maya Angelou Introduction Conatus Pharmaceuticals ( CNAT ) is a small cap ($52M) clinical stage biopharma. Emricasan, a dual anti-apoptotic/anti-inflammatory oral irreversible pan-caspase inhibitor, is its lead investigative P...